BRC branches into MS
08 February, 2006 by Helen SchullerThe Brain Resource Company (ASX:BRC) is to supply its services to a Schering Israel funded Multiple Sclerosis study.
CSL to enter US flu market, double vaccine capacity
08 February, 2006 by Ruth BeranBiopharmaceutical company CSL (ASX:CSL) will invest AUD$80 million in plant and equipment to double capacity at its Melbourne facility to 40 million doses per season, making it one of the largest vaccine manufacturing plants in the world.
In brief: Genesis Biomedical, Select Vaccines, Pharmaxis
06 February, 2006 by Helen SchullerSydney-based Genesis Biomedical (ASX:GBL) has closed its underwritten share offer early and oversubscribed raising AUD$2.4 million, substantially boosting its coffers -- the firm had $586,000 at the end of the quarter.
Ambri boss adds perspective to US partner's decision
06 February, 2006 by Helen SchullerSydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS).
Psiron chair spells out business plans
06 February, 2006 by Ruth BeranPsiron (ASX:PSX) has moved to reassure shareholders of its ability to fund its business plans, in the wake of last week's resignations of the company's CEO and CFO.
Glaxo opens Australian Relenza plant
06 February, 2006 by Ruth BeranFederal health minister Tony Abbott was on hand to cut the ribbon for the first of two Relenza production lines at GlaxoSmithKline's manufacturing facilities in Boronia, Victoria, last week.
Avantogen subsidiary and US company to merge
06 February, 2006 by Ruth BeranUS-listed Innovate Oncology and a wholly-owned subsidiary of Avantogen (ASX:ACU), formerly Australian Cancer Technologies, are to merge.
Portland initiates registration in China
03 February, 2006 by Helen SchullerPortland Orthopaedics (ASX:PLD) has initiated registration of its complete range of orthopaedic products with the State Drug Administration of China (SFDA), in a process expected to take 12 months.
Prana says study validates efficacy of Alzheimer's drug
03 February, 2006 by Graeme O'NeillMelbourne Alzheimer's disease (AD) drug developer Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) now has visual confirmation of its prototype plaque-buster, clioquinol, at work in an animal brain.
Ambri tech development dropped by US partner
02 February, 2006 by Helen SchullerBiosensor Enterprises (BEL) will no longer work to develop Sydney-based Ambri's (ASX:ABI) ion-channel switch (ICS), and will instead focus on out-licensing the technology.
In brief: Narhex, Norwood Abbey, Anadis, Phylogica
02 February, 2006 by Staff WritersNarhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.
Genepharm cheers regulatory approval
02 February, 2006 by Helen SchullerGeneric medicines company Genepharm Australasia's (ASX:GAA) brand of Simvastatin has been listed in the Australian Register of Therapeutic Goods, the final stage of TGA approval and registration process for its cholesterol-reducing drug.
Chemeq boosts manufacturing capacity
01 February, 2006 by Ruth BeranChemeq (ASX:CMQ) has upped the production capability of its Rockingham manufacturing facility, announcing today that it can now produce as much as 280,000 litres of the company's polymeric antimicrobial each year.
Road clear for Neuren phase III trials
01 February, 2006 by Helen SchullerThe US FDA has given the all-clear for Auckland biopharma Neuren Pharmaceuticals (ASX:NEU) to move straight into a phase III major efficacy trial for lead molecule Glypromate.
Norwood in Greek eyecare partnership
01 February, 2006 by Helen SchullerNorwood Abbey's (ASX:NAL) Norwood Eyecare division is to partner with the University of Crete, in Greece, on R&D in the field of Epi-LASIK refractive surgery and related innovations.
